Menu
Search
|

Menu

Close
X

Cellectar Biosciences Inc CLRB.OQ (NASDAQ Stock Exchange Capital Market)

6.69 USD
+0.43 (+6.87%)
As of Jul 20
chart
Previous Close 6.26
Open 6.87
Volume 55,392
3m Avg Volume 15,872
Today’s High 7.25
Today’s Low 6.43
52 Week High 20.50
52 Week Low 5.80
Shares Outstanding (mil) 17.71
Market Capitalization (mil) 110.86
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.068
FY17
-10.523
FY16
-3.527
FY15
-74.159
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
1.68
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
0.06
17.18
LT Debt to Equity (MRQ)
vs sector
0.02
13.08
Return on Investment (TTM)
vs sector
-132.51
13.18
Return on Equity (TTM)
vs sector
-151.68
15.09

EXECUTIVE LEADERSHIP

Stephen Hill
Chairman of the Board, Since 2007
Salary: --
Bonus: --
James Caruso
President, Chief Executive Officer, Director, Since 2015
Salary: $204,545.00
Bonus: --
Brian Posner
Chief Financial Officer, Vice President, Since 2018
Salary: --
Bonus: --
Cameron Szakacs
Vice President - Clinical Development, Since 2014
Salary: --
Bonus: --
Jarrod Longcor
Chief Business Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

3301 Agriculture Dr
MADISON   WI   53716-4133

Phone: +1608.4418120

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

SPONSORED STORIES